Ligand Reports Third Quarter 2020 Financial Results
Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment
Ligand Provides Highlights from Today’s Investor Day Event
Ligand’s Third Quarter Financial Results to be Reported October 30th
Ligand to Divest Vernalis Research Operations
Ligand to Host Virtual Investor Day on October 20th
Ligand Completes Acquisition of Pfenex Inc.
Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences
Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.
Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis
Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma
